X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
202 articles with X4 Pharmaceuticals
-
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
3/21/2023
X4 Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted key 2022 events and expected upcoming milestones.
-
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
3/7/2023
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 02, 2023
3/2/2023
X4 Pharmaceuticals announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
12/12/2022
X4 Pharmaceuticals today provided a summary of its chronic neutropenia-related presentations at this year’s annual meeting of the American Society of Hematology (ASH), taking place December 10-13, 2022 in New Orleans.
-
X4 Pharmaceuticals Prices $65.0 Million Public Offering
12/7/2022
X4 Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock at a price to the public of $1.10 per share and accompanying Class C warrant.
-
X4 Pharmaceuticals Announces Proposed Public Offering - December 06, 2022
12/6/2022
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock.
-
Four months after implementing a restructuring initiative to extend cash flow, X4 Pharmaceuticals is celebrating positive top-line results in WHIM syndrome.
-
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
11/29/2022
X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced positive top-line results from the global, pivotal Phase 3 clinical trial (4WHIM) of its lead investigational therapy, mavorixafor, a novel CXCR4 antagonist, in people with WHIM syndrome.
-
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
-
X4 Pharmaceuticals to Present at Stifel Healthcare Conference
11/8/2022
X4 Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 15, 2022.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022
11/4/2022
X4 Pharmaceuticals, Inc. announced that, effective on November 3, 2022, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/3/2022
X4 Pharmaceuticals reported financial results for the third quarter ended September 30, 2022 and highlighted recent and upcoming expected milestones.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
10/26/2022
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced the appointment of Mark Baldry to the position of Chief Commercial Officer.
-
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
10/20/2022
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2022 on November 3, 2022.
-
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
9/27/2022
X4 Pharmaceuticals, Inc. today announced new positive data from its Phase 1b clinical trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in people with idiopathic, cyclic, or congenital chronic neutropenia (CN) as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF).
-
X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic NeutropeniaWebcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A
8/31/2022
X4 Pharmaceuticals, Inc. announced that it will host an investor webinar to present and discuss new data from its Phase 1b trial evaluating its lead clinical candidate, mavorixafor, in patients with idiopathic, cyclic, and congenital neutropenia.
-
X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference
8/8/2022
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.
-
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
7/26/2022
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022.
-
Assembly Biosciences and X4 Pharmaceuticals have announced significant layoffs and reprioritization endeavors to let go of underperforming initiatives.